Cargando…

Everolimus Use for Intolerance or Failure of Baseline Immunosuppression in Adult Heart and Lung Transplantation

BACKGROUND: Everolimus can be utilized after heart or lung transplantation to reduce calcineurin inhibitor associated nephrotoxicity, due to cell cycle inhibitor adverse effects, and as adjunct therapy for rejection, cardiac allograft vasculopathy, and bronchiolitis obliterans syndrome. MATERIAL/MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kelsh, Shelby E., Girgis, Reda, Dickinson, Michael, McDermott, Jennifer K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2018
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248067/ https://www.ncbi.nlm.nih.gov/pubmed/30348935 http://dx.doi.org/10.12659/AOT.910952

Ejemplares similares

Individualizing immunosuppression in lung transplantation
por: McDermott, Jennifer K., et al.
Publicado: (2018)

Everolimus in Heart Transplantation: An Update
por: Hirt, Stephan W., et al.
Publicado: (2013)

Everolimus Based Immunosuppression Strategies in Adult Lung Transplant Recipients: Calcineurin Inhibitor Minimization Versus Calcineurin Inhibitor Elimination
por: Ivulich, Steven, et al.
Publicado: (2023)

Efficacy and Safety of Low-Dose Everolimus as Maintenance Immunosuppression in Cardiac Transplant Recipients
por: Fuchs, Uwe, et al.
Publicado: (2012)

Everolimus induced pneumonitis in a lung transplant recipient
por: Arunachalam, Ambalavanan, et al.
Publicado: (2018)

Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials
por: Liu, Jinyu, et al.
Publicado: (2017)

ALEMTUZUMAB FOR CHRONIC LUNG ALLOGRAFT DYSFUNCTION
por: Girgis, Reda, et al.
Publicado: (2020)

Cross-sectional analysis of immunosuppressive regimens focused on everolimus after liver transplantation in a Korean high-volume transplantation center
por: Kang, Sang-Hyun, et al.
Publicado: (2019)

Chronic Heart Failure and Exercise Intolerance: The Hemodynamic Paradox
por: Nilsson, Kent R, et al.
Publicado: (2008)

Contribution of Peripheral Chemoreceptors to Exercise Intolerance in Heart Failure
por: Kulej-Lyko, Katarzyna, et al.
Publicado: (2022)

The role of everolimus in liver transplantation
por: Ganschow, Rainer, et al.
Publicado: (2014)

Use of everolimus in liver transplantation
por: Yee, Mei-Ling, et al.
Publicado: (2017)

Early Introduction of Everolimus Immunosuppressive Regimen in Liver Transplantation with Extra-Anatomic Aortoiliac-Hepatic Arterial Graft Anastomosis
por: Felli, Emanuele, et al.
Publicado: (2014)

Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression
por: Peddi, V. Ram, et al.
Publicado: (2023)

Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen
por: Helmschrott, Matthias, et al.
Publicado: (2014)

Immunosuppressive strategies in lung transplantation
por: Chung, Paul A., et al.
Publicado: (2020)

New immunosuppressive drugs in heart transplantation
por: Costanzo, Maria Rosa
Publicado: (2001)

The use of everolimus in renal-transplant patients
por: Pascual, Julio
Publicado: (2009)

A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients
por: Chadban, Steven J, et al.
Publicado: (2014)

Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients
por: Bergh, Niklas, et al.
Publicado: (2020)

Belatacept for Maintenance Immunosuppression in Lung Transplantation
por: Hui, Christine, et al.
Publicado: (2014)

Review: immunosuppression for the lung transplant patient
por: Kotecha, Sakhee, et al.
Publicado: (2021)

Impact of maintenance immunosuppressive therapy on the fecal microbiome of renal transplant recipients: Comparison between an everolimus- and a standard tacrolimus-based regimen
por: Zaza, Gianluigi, et al.
Publicado: (2017)

An open-label randomized clinical trial to evaluate the efficacy of everolimus versus tacrolimus in triple maintenance immunosuppressive therapy for kidney transplant patients
por: Assis, B.P.S., et al.
Publicado: (2021)

Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem
por: Upadhya, Bharathi, et al.
Publicado: (2015)

Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?
por: Voorrips, Suzanne N., et al.
Publicado: (2022)

FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer
por: Chen, James L, et al.
Publicado: (2013)

A global perspective of lung transplantation: Part 1 - Recipient selection and choice of procedure
por: Girgis, Reda E., et al.
Publicado: (2016)

Eicosanoid and eicosanoid-related inflammatory mediators and exercise intolerance in heart failure with preserved ejection fraction
por: Lau, Emily S., et al.
Publicado: (2023)

Transfer of Everolimus into Colostrum of a Kidney Transplant Mother
por: Kociszewska-Najman, Bożena, et al.
Publicado: (2017)

Twelve-month effects of everolimus on renal and lung function in lung transplantation: differences in chronic lung allograft dysfunction phenotypes
por: Patrucco, Filippo, et al.
Publicado: (2021)

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
por: Bracarda, S, et al.
Publicado: (2012)

Enhanced Interleukin-1 Activity Contributes to Exercise Intolerance in Patients with Systolic Heart Failure
por: Van Tassell, Benjamin W., et al.
Publicado: (2012)

The fascial system and exercise intolerance in patients with chronic heart failure: hypothesis of osteopathic treatment
por: Bordoni, Bruno, et al.
Publicado: (2015)

Echocardiographic predictors of exercise intolerance in patients with heart failure with severely reduced ejection fraction
por: Zaborska, Beata, et al.
Publicado: (2018)

Metabolomic Profiling in Patients with Heart Failure and Exercise Intolerance: Kynurenine as a Potential Biomarker
por: Bekfani, Tarek, et al.
Publicado: (2022)

Rescue Everolimus Post Lung Transplantation is Not Associated With an Increased Incidence of CLAD or CLAD-Related Mortality
por: Ivulich, Steven, et al.
Publicado: (2023)

Baseline characteristics of 547 new onset heart failure patients in the PREFERS heart failure study
por: Linde, Cecilia, et al.
Publicado: (2022)

Association Between Renal Dysfunction and Major Adverse Cardiac Events After Liver Transplantation: Evidence from an International Randomized Trial of Everolimus-Based Immunosuppression
por: Saliba, Faouzi, et al.
Publicado: (2018)

Enhanced Humoral Immune Response After COVID-19 Vaccination in Elderly Kidney Transplant Recipients on Everolimus Versus Mycophenolate Mofetil–containing Immunosuppressive Regimens
por: de Boer, Silke E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rtd3vqotsdb9htpdhsqfvtbuqn